Superworth

Neurocrine Biosciences price to sales ratio NBIX

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026
4.3×
9-year median
7.8×
Against its 9-year history
1st
percentile: 0 is its lowest day, 100 its highest
9-year range
3.8× to 117×
Peer median
7.5×

Neurocrine Biosciences' price to sales ratio is 4.3× as of Oct 23, 2026.

That is below its 9-year median of 7.8×, lower than on 99% of days in the last 9 years.

Over that time it ranged from 3.8× in Apr 2025 to 117× in Jan 2018.

The median for 10 biotech stocks of a similar size is 7.5×.

Price to sales ratio over time

The dashed line is the 9-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far4.3×4.1×5.7×
20255.4×3.8×6.9×
20246.3×5.3×7.8×
20237.3×5.6×8.5×
20228.3×6.3×8.8×
20217.6×7.1×10.5×
20208.6×8.0×15.3×
201914.8×13.6×20.0×
201815.0×15.0×117×
2017102×93.0×102×
2016199×153×199×
2015191×153×199×
201447.3×26.9×54.8×
201326.0×13.1×33.0×
201211.6×5.7×12.4×

Against its peers

Companies in Biotechnology nearest Neurocrine Biosciences' size, closest first, today.

CompanyPrice to sales ratio
NBIXNeurocrine Biosciences4.3×
HALOHalozyme Therapeutics8.6×
EXELExelixis6.6×
TECHBIO-TECHNE9.4×
RGENRepligen12.7×
KRYSKrystal Biotech20.9×
INCYIncyte4.0×
UTHRUnited Therapeutics8.0×
ALNYAlnylam Pharmaceuticals6.2×
ONCBeOne Medicines7.0×
REGNRegeneron Pharmaceuticals5.3×
Peer median7.5×

Where Neurocrine Biosciences ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Neurocrine Biosciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.